The FreeStyle Libre 3 system helped Nathan manage his diabetes. Now, he's sharing his story to help lift stigma.Abbott NORTHAMPTON, MA / ACCESS Newswire / February 7, 2025 / As a competitive powerlift ...

The FreeStyle Libre 3 system helped Nathan manage his diabetes. Now, he's sharing his story to help lift stigma. Abbott NORTHAMPTON, MA / ACCESS Newswire / February 7, 2025 / As a competitive ...

Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose ...

One cupcake won't kill you,' 'I'm going to get diabetes just looking at that,' 'That person doesn't look like they have ...

Argus analyst David Toung raised the firm’s price target on Abbott (ABT) to $150 from $145 and keeps a Buy rating on the shares. Abbott’s ...

Libre Drives Diabetes Care: Abbott’s Diabetes Care business continued to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.

Built on the FreeStyle Libre continuous glucose monitoring technology—now used by more than 6 million people with diabetes globally—Lingo tracks users' glucose levels continuously. The system is ...

Abbott had been facing supply issues for its Libre devices and said it will meet the demand mismatch as it gets one of its manufacturing sites up and running. Advt Shares of the company rose 1.3% ...

Abbott has won an innovation award for Lingo, its first consumer biowearable over-the-counter device to empower people in improving overall health and wellness.

Abbott reported Q4 sales of $11 billion missing the consensus; adjusted EPS was $1.34, matching analyst estimates Medical Device sales surged 13.7% to $5.05 billion, with FreeStyle Libre and AVEIR ...